Literature DB >> 33738294

Challenges in Transition From Childhood to Adulthood Care in Rare Metabolic Diseases: Results From the First Multi-Center European Survey.

Karolina M Stepien1, Beata Kieć-Wilk2,3, Christina Lampe4, Trine Tangeraas5, Graziella Cefalo6, Nadia Belmatoug7, Rita Francisco8, Mireia Del Toro9, Leona Wagner10, Anne-Grethe Lauridsen11,12, Sylvia Sestini13, Nathalie Weinhold14, Andreas Hahn15, Chiara Montanari6, Valentina Rovelli6, Cinzia M Bellettato16, Laura Paneghetti16, Corine van Lingen16, Maurizio Scarpa16.   

Abstract

Inherited Metabolic Diseases (IMDs) are rare diseases caused by genetic defects in biochemical pathways. Earlier diagnosis and advances in treatment have improved the life expectancy of IMD patients over the last decades, with the majority of patients now surviving beyond the age of 20. This has created a new challenge: as they grow up, the care of IMD patients' needs to be transferred from metabolic pediatricians to metabolic physicians specialized in treating adults, through a process called "transition." The purpose of this study was to assess how this transition is managed in Europe: a survey was sent to all 77 centers of the European Reference Network for Hereditary Metabolic Disorders (MetabERN) to collect information and to identify unmet needs regarding the transition process. Data was collected from 63/77 (81%) healthcare providers (HCPs) from 20 EU countries. Responders were mostly metabolic pediatricians; of these, only ~40% have received appropriate training in health issues of adolescent metabolic patients. In most centers (~67%) there is no designated transition coordinator. About 50% of centers provide a written individualized transition protocol, which is standardized in just ~20% of cases. In 77% of centers, pediatricians share a medical summary, transition letter and emergency plan with the adult team and the patient. According to our responders, 11% of patients remain under pediatric care throughout their life. The main challenges identified by HCPs in managing transition are lack of time and shortage of adult metabolic physician positions, while the implementations that are most required for a successful transition include: medical staff dedicated to transition, a transition coordinator, and specific metabolic training for adult physicians. Our study shows that the transition process of IMD patients in Europe is far from standardized and in most cases is inadequate or non-existent. A transition coordinator to facilitate collaboration between the pediatric and adult healthcare teams should be central to any transition program. Standardized operating procedures, together with adequate financial resources and specific training for adult physicians focused on IMDs are the key aspects that must be improved in the rare metabolic field to establish successful transition processes in Europe.
Copyright © 2021 Stepien, Kieć-Wilk, Lampe, Tangeraas, Cefalo, Belmatoug, Francisco, del Toro, Wagner, Lauridsen, Sestini, Weinhold, Hahn, Montanari, Rovelli, Bellettato, Paneghetti, van Lingen and Scarpa.

Entities:  

Keywords:  adult metabolic patient; adulthood (18 years and older); challenge; continuity of care; inherited metabolic disease(s); rare disease; transition process

Year:  2021        PMID: 33738294      PMCID: PMC7962750          DOI: 10.3389/fmed.2021.652358

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  12 in total

Review 1.  Unmet Cardiac Clinical Needs in Adult Mucopolysaccharidoses.

Authors:  Karolina M Stepien; Elizabeth A Braunlin
Journal:  Front Cardiovasc Med       Date:  2022-06-10

2.  Application of the Artificial Intelligence Algorithm Model for Screening of Inborn Errors of Metabolism.

Authors:  Muping Zhou; Liyuan Deng; Yan Huang; Ying Xiao; Jun Wen; Na Liu; Yingchao Zeng; Hua Zhang
Journal:  Front Pediatr       Date:  2022-05-19       Impact factor: 3.569

3.  Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries.

Authors:  Martin Magner; Zsuzsanna Almássy; Zoran Gucev; Beata Kieć-Wilk; Vasilica Plaiasu; Anna Tylki-Szymańska; Dimitrios Zafeiriou; Ioannis Zaganas; Christina Lampe
Journal:  Orphanet J Rare Dis       Date:  2022-05-10       Impact factor: 4.303

4.  Unmet Needs of Parents of Children with Urea Cycle Disorders.

Authors:  Mara Scharping; Heiko Brennenstuhl; Sven F Garbade; Beate Wild; Roland Posset; Matthias Zielonka; Stefan Kölker; Markus W Haun; Thomas Opladen
Journal:  Children (Basel)       Date:  2022-05-12

Review 5.  Multidisciplinary Care of Patients with Inherited Metabolic Diseases and Epilepsy: Current Perspectives.

Authors:  Birutė Tumienė; Mireia Del Toro Riera; Jurgita Grikiniene; Rūta Samaitiene-Aleknienė; Rūta Praninskienė; Ahmad Ardeshir Monavari; Jolanta Sykut-Cegielska
Journal:  J Multidiscip Healthc       Date:  2022-03-25

Review 6.  Current challenges and opportunities in the care of patients with fibrodysplasia ossificans progressiva (FOP): an international, multi-stakeholder perspective.

Authors:  Robert J Pignolo; Christopher Bedford-Gay; Amanda Cali; Michelle Davis; Patricia L R Delai; Kristi Gonzales; Candace Hixson; Alastair Kent; Hope Newport; Manuel Robert; Christiaan Scott; Frederick S Kaplan
Journal:  Orphanet J Rare Dis       Date:  2022-04-18       Impact factor: 4.303

7.  Maple syrup urine disease decompensation misdiagnosed as a psychotic event.

Authors:  Tomoyasu Higashimoto; Matthew T Whitehead; Erin MacLeod; Danielle Starin; Debra S Regier
Journal:  Mol Genet Metab Rep       Date:  2022-06-18

Review 8.  Psychosocial Considerations for the Child with Rare Disease: A Review with Recommendations and Calls to Action.

Authors:  Leslee T Belzer; S Margaret Wright; Emily J Goodwin; Mehar N Singh; Brian S Carter
Journal:  Children (Basel)       Date:  2022-06-21

9.  Personalized medicine for rare neurogenetic disorders: can we make it happen?

Authors:  Agnies M van Eeghen; Hilgo Bruining; Nicole I Wolf; Arthur A Bergen; Riekelt H Houtkooper; Mieke M van Haelst; Clara D van Karnebeek
Journal:  Cold Spring Harb Mol Case Stud       Date:  2022-03-24

10.  The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers.

Authors:  Anna Tylki-Szymańska; Zsuzsanna Almássy; Violetta Christophidou-Anastasiadou; Daniela Avdjieva-Tzavella; Ingeborg Barisic; Rimante Cerkauskiene; Goran Cuturilo; Maja Djiordjevic; Zoran Gucev; Anna Hlavata; Beata Kieć-Wilk; Martin Magner; Ivan Pecin; Vasilica Plaiasu; Mira Samardzic; Dimitrios Zafeiriou; Ioannis Zaganas; Christina Lampe
Journal:  Orphanet J Rare Dis       Date:  2022-03-24       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.